While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...

After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

National Geographic photographer Josh Cogan captures the quiet power of Hawaii’s ocean life, revealing how resilience shows ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and ...

CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...

Citi raised the firm’s price target on Argenx (ARGX) to $1,124 from $1,041 and keeps a Buy rating on the shares. The firm left a meeting with ...

VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...

Chronic Inflammatory Demyelinating Polyneuropathy — or CIDP — is a rare but treatable nerve condition. It happens when the body’s immune system mistakenly attacks the protective covering (called ...